In vivo binding and antitumor activity of Ch14.18 - PubMed (original) (raw)

In vivo binding and antitumor activity of Ch14.18

K Kendra et al. J Immunother. 1999 Sep.

Abstract

The melanoma reactive chimeric 14.18 (ch14.18) antibody can mediate enhanced in vitro lysis of human M-21 melanoma cells. This study analyzes the antitumor effects and the in vivo binding of ch14.18 antibody with M-21 melanoma cells in severe combined immunodeficiency (SCID) mice. Outgrowth of tumors was prevented in 6/6 animals by the simultaneous subcutaneous injection of peripheral blood mononuclear cells (PBMC) [3 x 10(6) cells (2 animals); 10 x 10(6) cells (2 animals); and 30 x 10(6) cells (2 animals)], with 0.5 mg ch14.18, 1,500 U interleukin 2 (IL-2), and 10(6) M-21 cells. In contrast, 7 of 7 control mice that received M-21 cells alone, 7 of 7 mice that received M-21 cells and ch14.18, and 5 of 6 mice that received M-21 cells plus PBMC plus IL-2, grew subcutaneous tumors. The in vivo localization of ch14.18 was then evaluated in an intraperitoneal (i.p.) tumor model, where 0.3 cm melanoma nodules develop within 3 weeks after the i.p. administration of M-21 cells. Flow cytometric and immunohistochemical analysis revealed the GD2 antigen present throughout the tumor nodule. Intraperitoneal administration of 0.01, 0.1, or 1.0 mg of ch14.18 to SCID mice previously engrafted i.p. with M-21 cells resulted in detectable ch14.18 binding to tumor cells in vivo within 10 hours of antibody administration. Ch14.18 penetration was limited to approximately 20 cell layers, demonstrating that ch14.18 has limited access to some cells in large tumor nodules. This study demonstrates that the addition of ch14.18 to IL-2 and human effector cells can result in significant antitumor activity by preventing the establishment of tumor nodules. These results suggest that clinical testing of IL-2 plus ch14.18 might be most effective if used in the setting of microscopic residual disease. Therapies that enhance ch14.18 penetration into tumor nodules should be evaluated with ch14.18 for patients with advanced melanoma.

PubMed Disclaimer

Similar articles

• Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
  Albertini MR, Hank JA, Schiller JH, Khorsand M, Borchert AA, Gan J, Bechhofer R, Storer B, Reisfeld RA, Sondel PM. Albertini MR, et al. Clin Cancer Res. 1997 Aug;3(8):1277-88. Clin Cancer Res. 1997. PMID: 9815810 Clinical Trial.
• Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.
  Saleh MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Grizzle W, Reisfeld RA, Yu AL, Gillies SD, LoBuglio AF. Saleh MN, et al. Hum Antibodies Hybridomas. 1992 Jan;3(1):19-24. Hum Antibodies Hybridomas. 1992. PMID: 1576319 Clinical Trial.
• Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
  Sondel PM, Hank JA. Sondel PM, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S121-7. Cancer J Sci Am. 1997. PMID: 9457407 Review.
• Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.
  Albertini MR, Gan J, Jaeger P, Hank JA, Storer B, Schell K, Rivest T, Surfus J, Reisfeld RA, Schiller JH, Sondel PM. Albertini MR, et al. J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):278-95. doi: 10.1097/00002371-199607000-00004. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8877722
• Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
  Parsons K, Bernhardt B, Strickland B. Parsons K, et al. Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Ann Pharmacother. 2013. PMID: 23386066 Review.

Cited by

• IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
  Stip MC, Evers M, Nederend M, Chan C, Reiding KR, Damen MJ, Heck AJR, Koustoulidou S, Ramakers R, Krijger GC, de Roos R, Souteyrand E, Cornel AM, Dierselhuis MP, Jansen M, de Boer M, Valerius T, van Tetering G, Leusen JHW, Meyer-Wentrup F. Stip MC, et al. J Immunother Cancer. 2023 Jul;11(7):e006948. doi: 10.1136/jitc-2023-006948. J Immunother Cancer. 2023. PMID: 37479484 Free PMC article.
• Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
  Desai AV, Gilman AL, Ozkaynak MF, Naranjo A, London WB, Tenney SC, Diccianni M, Hank JA, Parisi MT, Shulkin BL, Smith M, Moscow JA, Shimada H, Matthay KK, Cohn SL, Maris JM, Bagatell R, Sondel PM, Park JR, Yu AL. Desai AV, et al. J Clin Oncol. 2022 Dec 10;40(35):4107-4118. doi: 10.1200/JCO.21.02478. Epub 2022 Jul 15. J Clin Oncol. 2022. PMID: 35839426 Free PMC article.
• The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy.
  Hamilton G, Plangger A. Hamilton G, et al. Biologics. 2021 Jul 7;15:265-277. doi: 10.2147/BTT.S290305. eCollection 2021. Biologics. 2021. PMID: 34262255 Free PMC article. Review.
• Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells.
  Ly S, Anand V, El-Dana F, Nguyen K, Cai Y, Cai S, Piwnica-Worms H, Tripathy D, Sahin AA, Andreeff M, Battula VL. Ly S, et al. J Immunother Cancer. 2021 Mar;9(3):e001197. doi: 10.1136/jitc-2020-001197. J Immunother Cancer. 2021. PMID: 33722905 Free PMC article.
• The Advances and Challenges of NK Cell-Based Cancer Immunotherapy.
  Kang S, Gao X, Zhang L, Yang E, Li Y, Yu L. Kang S, et al. Curr Oncol. 2021 Feb 26;28(2):1077-1093. doi: 10.3390/curroncol28020105. Curr Oncol. 2021. PMID: 33652996 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.